Par To Pay $45M For Off-Label Marketing Of AIDS Drug
New Jersey-based Par Pharmaceutical Cos. Inc. agreed Tuesday to pay $45 million to settle civil and criminal claims alleging the company mismarketed its Megace ES AIDS weight-enhancement drug as suitable for...To view the full article, register now.
Already a subscriber? Click here to view full article